Document Detail


Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
MedLine Citation:
PMID:  18926235     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increased pulmonary vascular resistance causing pulmonary artery hypertension is a major problem in the treatment of congenital diaphragmatic hernia with a strong association to mortality. We here report a patient with intractable pulmonary hypertension at 4 weeks of age unresponsive to conventional treatment. After administration of the platelet-derived growth factor (PDGF) receptor antagonist imatinib, pulmonary artery pressure gradually decreased to acceptable levels and the patient's clinical condition gradually improved.
Authors:
Björn Frenckner; Michael Broomé; Maria Lindström; Peter Radell
Related Documents :
19805635 - Hypertension correlates with lenticulostriate arteries visualized by 7t magnetic resona...
15699255 - Retinoids and pulmonary hypertension.
14726295 - Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats.
7914075 - Pharmacotherapy of chronic pulmonary arterial hypertension: value and limitations. part...
9806675 - Pulmonary arterial and right ventricular responses to prophylactic albumin administrati...
17803475 - Vascular calcification and arterial stiffness in chronic kidney disease: implications a...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of pediatric surgery     Volume:  43     ISSN:  1531-5037     ISO Abbreviation:  J. Pediatr. Surg.     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-10-17     Completed Date:  2009-02-23     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  0052631     Medline TA:  J Pediatr Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1928-31     Citation Subset:  IM    
Affiliation:
Department of Pediatric Surgery, Astrid Lindgren Children's Hospital, Karolinska Institutet, SE-171 76 Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anoxia / drug therapy,  etiology,  therapy
Combined Modality Therapy
Continuous Positive Airway Pressure
Diuretics / therapeutic use
Enteral Nutrition
Extracorporeal Membrane Oxygenation
Heart Failure / etiology
Hernia, Diaphragmatic / complications*,  congenital,  surgery
Humans
Hypertension, Pulmonary / drug therapy*,  etiology
Iloprost / therapeutic use
Infant, Newborn
Male
Nitric Oxide / therapeutic use
Piperazines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Purines / therapeutic use
Pyrimidines / therapeutic use*
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors*
Sulfonamides / therapeutic use
Sulfones / therapeutic use
Chemical
Reg. No./Substance:
0/Diuretics; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Purines; 0/Pyrimidines; 0/Sulfonamides; 0/Sulfones; 10102-43-9/Nitric Oxide; 3M7OB98Y7H/sildenafil; 78919-13-8/Iloprost; BKJ8M8G5HI/imatinib; EC 2.7.10.1/Receptors, Platelet-Derived Growth Factor; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mesenteric pseudoaneurysm and cerebral stroke as sequelae of infective endocarditis in an adolescent...
Next Document:  Modified digestive reconstruction with midgut transposition after pylorus-preserving pancreaticoduod...